Abstract
Many plants produce enzymes with N-glycosidase activity, also known as Ribosome Inactivating Proteins. These proteins remove a specific adenine residue from the ribosomal RNA (28S in eukaryotes) inducing the block of protein synthesis by inhibiting the binding of the Elongation Factor 2. Both eukaryotic and prokaryotic ribosomes (with different sensitivity) can irreversibly be damaged by the action of these enzymes, suggesting their use as cytotoxic drugs. In fact several applications of targeted N-glycosidases have been developed (i.e. immunotoxins) for the treatment of human diseases such as leukaemia, but biotechnological development has furthermore suggested new applications of targeted N-glycosidases (i.e. Ig192-saporin) that are now used as powerful tools for cell biology research. The high number of enzymes available and the possibility to express these proteins as recombinant products, allow to predict new formulations and applications discussed in this paper starting from the example of the model toxins ricin and saporin.
Keywords: N-glycosidases, Saporin, Ricin, toxins, immunotoxins
Current Chemical Biology
Title: Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Volume: 4 Issue: 2
Author(s): Francesco Giansanti, Luana Di Leandro, Ilias Koutris, Alessio Cialfi, Elisabetta Benedetti, Giulio Laurenti, Giuseppina Pitari and Rodolfo Ippoliti
Affiliation:
Keywords: N-glycosidases, Saporin, Ricin, toxins, immunotoxins
Abstract: Many plants produce enzymes with N-glycosidase activity, also known as Ribosome Inactivating Proteins. These proteins remove a specific adenine residue from the ribosomal RNA (28S in eukaryotes) inducing the block of protein synthesis by inhibiting the binding of the Elongation Factor 2. Both eukaryotic and prokaryotic ribosomes (with different sensitivity) can irreversibly be damaged by the action of these enzymes, suggesting their use as cytotoxic drugs. In fact several applications of targeted N-glycosidases have been developed (i.e. immunotoxins) for the treatment of human diseases such as leukaemia, but biotechnological development has furthermore suggested new applications of targeted N-glycosidases (i.e. Ig192-saporin) that are now used as powerful tools for cell biology research. The high number of enzymes available and the possibility to express these proteins as recombinant products, allow to predict new formulations and applications discussed in this paper starting from the example of the model toxins ricin and saporin.
Export Options
About this article
Cite this article as:
Giansanti Francesco, Di Leandro Luana, Koutris Ilias, Cialfi Alessio, Benedetti Elisabetta, Laurenti Giulio, Pitari Giuseppina and Ippoliti Rodolfo, Ricin and Saporin: Plant Enzymes for the Research and the Clinics, Current Chemical Biology 2010; 4 (2) . https://dx.doi.org/10.2174/2212796811004020099
DOI https://dx.doi.org/10.2174/2212796811004020099 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Chemical Libraries Towards Protein Kinase Inhibitors
Combinatorial Chemistry & High Throughput Screening The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Knemometry for Assessment of Growth Suppressive Effects of Exogenous Glucocorticoids
Current Pediatric Reviews A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety